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Edited by Hans-Dieter KlenkAbstract The open reading frame 3 of the severe acute
respiratory syndrome coronavirus (SARS-CoV) genome encodes
a predicted protein 3a, consisting of 274 amino acids, that lacks
any signiﬁcant similarities to any known protein. We generated
speciﬁc antibodies against SARS protein 3a by using a synthetic
peptide (P2) corresponding to amino acids 261–274 of the
putative protein. Anti-P2 antibodies and the sera from SARS
patients could speciﬁcally detect the recombinant SARS protein
3a expressed in Escherichia coli and in Vero E6 cells. Expression
of SARS protein 3a was detected at 8–12 h after infection and
reached a higher level after 24 h in SARS-CoV-infected Vero
E6 cells. Protein 3a was also detected in the alveolar lining
pneumocytes and some intra-alveolar cells of a SARS-CoV-
infected patient’s lung specimen. Recombinant protein 3a
expressed in Vero E6 cells and protein 3a in the SARS-CoV-
infected cells was distributed over the cytoplasm in a ﬁne
punctate pattern with partly concentrated staining in the Golgi
apparatus. Our study demonstrates that SARS-CoV indeed
expresses a novel protein 3a, which is present only in SARS-CoV
and not in other known CoVs.
 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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An epidemic of severe acute respiratory syndrome (SARS)
has been associated with an outbreak of atypical pneumonia
in many countries [1,2]. There is now clear evidence that a* Corresponding author. Fax: +886-2-2395-7801.
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Abbreviations: SARS, severe acute respiratory syndrome; CoV, coro-
navirus
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[3,4]. Genome sequences of SARS-CoV isolates obtained
from clinical index patients have been published and are
available in the GenBank (http://www.ncbi.nlm.nih.gov/).
Coronaviruses are exceptionally large RNA viruses. The
genome of SARS-CoV is 29.7 kb in length and has the
same frame of sequence structure as do other CoVs such as
the spike glycoprotein (S), envelope protein (E), membrane
protein (M), and nucleocapsid protein (N), which have been
identiﬁed in SARS-CoV [5]. However, 14 putative open
reading frames (ORFs) were identiﬁed within the SARS-
CoV genome, encoding six known and eight unknown
proteins [6,7]. Theoretically, all of these proteins play a
unique and important role as SARS-CoV infection pro-
gresses and could serve as targets for addressing the
mechanisms and therapeutic developments for this disease.
For example, the four structural proteins: the S protein, M
protein, N protein, and small E protein have been broadly
studied for their important roles in receptor binding, virion
budding, and viral life cycle during general processes of
viral infection [8,9]. The gene of ORF 3a (CDS: 25268–
26092) is located between the gene of the S glycoprotein
(CDS: 21492–25259) and E protein (CDS: 26117–26347)
[6,7]. The minimal transcription regulatory sequence (50-
ACGAAC-30) is also located upstream of ORF 3a (CDS:
25260–25265) [7]. Due to its novelty, we investigated ORF
3a that encodes the putative protein 3a, designated as
protein X1 by Rota et al. [4].
In this study, we demonstrated that protein 3a was ex-
pressed in SARS-CoV-infected cells and a SARS-CoV-in-
fected patient’s lung specimen. Protein 3a was a membrane
associated protein that was distributed over the cytoplasm in
a ﬁne punctate pattern with partly concentrated staining in
the Golgi apparatus. In addition, speciﬁc antibodies against
protein 3a were also present in sera from SARS-CoV-infected
patients. Thus, the identiﬁcation of this novel protein 3a
could be the ﬁrst step toward exploring its role in the SARS
infection process and the potential utilization of protein 3a in
clinical diagnosis or therapeutic development.blished by Elsevier B.V. All rights reserved.
112 C.-J. Yu et al. / FEBS Letters 565 (2004) 111–1162. Materials and methods
2.1. Cloning and expression of protein 3a
SARS-CoV total RNA was isolated from SARS-CoV (TW1
strain)-infected Vero E6 cells by a single-step extraction method as
described previously [10,11]. Oligonucleotide primers used for am-
pliﬁcation and sequencing of the protein 3a gene were based on the
SARS-CoV-TW1 sequence (Accession No. AY291451). Two oligo-
nucleotides based on the N- and C-terminal sequences of the protein
3a gene were synthesized. The sense primer used was 50-AT-
GGATTTGTTTATGAGATTTTTTACT-30, encoding the eight N-
terminal amino acids (MDLFMRFFT), whereas the antisense
primer was 50-CAAAGGCACGCTAGTAGTCGTCGT-30, encoding
the C-terminus (TTTTSVPL). The coding sequence of the protein 3a
gene was then ampliﬁed by PCR, and the ampliﬁed product was
analyzed by electrophoresis, subcloned into the pSTBlue vector
(Novagen, Madison, WI), then transformed into Escherichia coli
strain DH5. After transformation, plasmids from positive clones
were subjected to sequence analysis by use of an ABI 3100 se-
quencer (Applied Biosystems, Foster City, CA) and the dye termi-
nator cycle sequencing FS Ready reaction. For expression of the
recombinant protein 3a, the SARS virus protein 3a gene from the
pSTBlue construct was inserted into vector pGEX 4T-2 (Amersham
Biosciences Inc., Sweden) in frame with the EcoRI restriction en-
zyme site for expression as a glutathione S-transferase (GST) fusion
protein. After being transformed into E. coli strain BL21 (DE3)
(Novagen, Madison, WI), the fusion protein was expressed by in-
duction with 0.5 mM isopropyl-b-D-thiogalactopyranoside, for 3 h
at 37 C. For obtaining the pure recombinant protein 3a, the GST-
fusion protein was aﬃnity puriﬁed by glutathione–Sepharose 4B
chromatography (Amersham Biosciences Inc.) according to the
manufacturer’s instructions. The recombinant protein 3a was then
released from the Sepharose-bound GST moiety by speciﬁc digestion
with thrombin protease and collected. Brieﬂy, the induced cells were
suspended in phosphate-buﬀered saline (PBS) buﬀer with 1 mM
phenylmethanesulfonyl ﬂuoride and then sonicated in an ice bath
for 1 min. The lysed cells were centrifuged at 20000 g at 4 C for
15 min and the pellets were discarded. The supernatant was applied
to a glutathione–Sepharose 4B column equilibrated with PBS buﬀer
and the column was washed with 10 the bed volume of the same
buﬀer. After the GST-fusion SARS protein 3a was bound, the
column was incubated with PBS containing 50 units of thrombin at
25 C for 2 h. The released recombinant protein 3a lacking the GST
carrier was eluted with PBS buﬀer and collected. The protein purity
was determined by 12.5% SDS–PAGE electrophoresis and visualized
with Coomassie blue.
For transient expression of the recombinant protein 3a in Vero E6
cells, the coding region of protein 3a was subcloned into the EcoRI
site of the pcDNA3.1/myc-His vector (Invitrogen, San Diego, CA).
Vero E6 (ATCC CRL-1586) cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM, Gibco-BRL) supplemented with
2 mM L-glutamine, 1% penicillin/streptomycin, and 10% fetal bovine
serum. The pcDNA3.1/Myc-His/protein 3a plasmid was mixed with
Lipofectin reagent (Invitrogen, San Diego, CA) according to the
manufacturer’s instructions, and approximately 15 lg of DNA was
transfected into 1 106 Vero E6 cells that had been infected 2 h
earlier with 1 105 infectious units of a vaccinia virus/bacteriophage
T7 RNA polymerase hybrid [12–14]. After 48 h, cells were har-
vested, washed twice with PBS, and then the expression of protein
3a was veriﬁed by Western blotting.
2.2. Polyclonal antibody preparation
New Zealand White rabbits were immunized with keyhole limpet
hemocyanin-conjugated synthetic peptide CPIYDEPTTTTSVPL
(peptide P2), corresponding to residues 261–274 of protein 3a, or
SDNGPQSNQRSAC (peptide N1), corresponding to residues 1–12
of the nucleocapsid protein. The conjugated-peptides in 0.5 ml of
PBS were emulsiﬁed with an equal volume of Titer Max adjuvant
(CytRx Inc., Norcross, GA) and 3-month-old rabbits were immu-
nized. After 3 weeks, boosters of each conjugated-peptide emulsiﬁed
in Freund’s incomplete adjuvant were given by intradermal injec-
tion; this was followed by another injection of peptide in another 3
weeks. Anti-sera were collected at 12-day intervals starting from the
last boost and the IgG speciﬁcity was monitored by Western blot-
ting assay.2.3. Immunodetection assays
Protein samples were separated by SDS–PAGE on a 12.5% sepa-
ration gel. For immunodetection of the antigenicity of protein 3a, the
separated proteins were electroblotted onto a PVDF membrane, which
was then blocked with skimmed milk and incubated for 16 h at 4 C
with anti-P2 rabbit anti-serum diluted 1:2000–3000 or a human serum
pool diluted 1:100. Bound IgG antibodies were detected by use of
horseradish peroxidase-labeled donkey anti-rabbit IgG antibodies
(Amersham Biosciences Inc.) or sheep anti-human IgG antibodies
(Amersham Biosciences Inc.). The target proteins were revealed by an
enhanced chemiluminescence (ECL, Amersham Biosciences Inc.) de-
velopment system.
2.4. Immunohistochemistry assay
A 73-year-old man was admitted to National Taiwan University
Hospital because of recurrent chest pain and dyspnea on April 23,
2003. He had an episode of myocardial infarction two years before.
After admission, a low-grade fever developed and serial follow-up
chest X-rays showed progressive lung inﬁltration. SARS-CoV was
isolated from his throat swab and RT-PCR for SARS-CoV further
conﬁrmed the presence of viral genome in the specimen of his throat
swab. He died of acute myocardial infarction at the 7th day after
admission. A restricted autopsy was performed immediately, random
sampling of the lungs, heart, kidneys, liver, small intestine, and spleen
was taken. All the tissue specimens were ﬁxed in 10% neutral formalin
and paraﬃn-embedded blocks and serial sections were prepared in a
conventional manner. The hematoxylin and eosin staining of the lung
tissue from this SARS patient showed congestion and focal edema.
Another three lung biopsy specimens without SARS-CoV infection
were also analyzed as negative controls. For immunohistochemical
staining, antigen retrieval was carried out with the steam heat method
for 10 min using the Trilogy retrieval buﬀer. (Cell Marque Coopera-
tion, Austin, TX). Endogenous peroxidase activity was quenched with
0.3% hydrogen peroxide for 20 min. For SARS-CoV detection anti-P2
antibody diluted in 1:500 was used. Pre-immune rabbit serum was used
as a negative control. The previously heat-treated tissue sections were
incubated with the primary antibodies and non-immune serum at 4 C
overnight. The slides were then sequentially stained on a Nexis auto-
stainer (Ventana, Tucson, AZ) using the Ventana Basic Alkaline
Phosphatase Red Detection Kit (Ventana) and counterstained with
hematoxylin.
2.5. Immunoﬂuorescence microscopy
About 6 104 Vero E6 cells were grown on coverslips within 12-well
plates and then infected /transfected with 1 lg pcDNA3.1/myc-His
protein 3a plasmid by Lipofectin reagent (Invitrogen, San Diego, CA)
as described above. After 48 h, cells were washed with PBS twice
followed by ﬁxation with 4% paraformaldehyde in PBS for 5 min at
room temperature and permeabilized in methanol for 5 min on ice.
Indirect immunoﬂuorescence staining was performed as described
previously [15]. The cells were blocked with 0.2% bovine serum albu-
min, 0.1% saponin in PBS, followed by incubation with anti-P2
peptide-speciﬁc rabbit anti-serum or anti-SARS M protein rabbit anti-
serum for 30 min. Mouse monoclonal antibodies to Golgi 58K protein
(Sigma), mouse monoclonal antibodies to b-COP protein (Sigma),
mouse monoclonal antibodies to calnexin protein (Aﬃnity BioRe-
agents), mouse monoclonal antibodies to lysosomal-associated mem-
brane proteins-2 (LAPM-2) (BD Biosciences) or mouse monoclonal
antibodies to cytochrome c oxidase subunit 1 (COX 1) (Molecular
Probes) were diluted in 1:100 and co-incubated with anti-P2 antibody,
respectively. The optimal anti-P2 anti-serum dilution (1:600) for the
use of SARS-protein 3a was determined by titration experiments on
non-infected cells. After three washes with PBS, cells were incubated
with secondary antibody, Alexa 488-conjugated anti-rabbit IgG anti-
body (Molecular Probes), Alexa 594-conjugated anti-mouse IgG an-
tibody, and Hoechst 33258 (DNA-binding dye). Finally, cells were
washed 3 with PBS, mounted on Mowiol, and examined with a Zeiss
Axiophot microscope equipped for epiﬂuorescence and a Bio-Rad
Radiance 2100 confocal microscope for confocal ﬂuorescence.
2.6. Subcellular fractionation
Cytosol (C) and membrane (M) fractions of Vero E6 cells were
prepared using a CNM compartment protein extraction kit (BioChain
Institute Inc., Hayward, CA) according to the manufacturer’s in-
structions. Brieﬂy, infected–transfected Vero E6 cells (1 106 cells)
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5 min. The cell pellet was homogenized in 100 ll of buﬀer C plus a
mixture of protease inhibitors, rotated at 4 C for 20 min followed by
centrifugation at 4 C, 12000 g for 20 min to generate soluble cy-
tosolic (C) fraction. The insoluble pellet was washed with 200 ll of
buﬀer W and resuspended in 50 ll of buﬀer N at 4 C for 20 min. The
nuclear proteins (N) were extracted and recovered in the supernatant
after centrifugation at 4 C, 12000 g for 20 min. Finally, to obtain
the membrane proteins, the cell pellet containing cell debris was ex-
tracted with 50 ll of buﬀer M and then rotated at 4 C for 20 min. The
supernatant was centrifuged at 4 C, 12000 g for 20 min to generate
soluble membrane (M) fraction. All of the fractionated protein solu-
tions were stored at )70 C until analyzed.3. Results and discussion
3.1. Analysis of the novel SARS-CoV protein 3a
The ORF 3a of the SARS-CoV genome encodes a predicted
protein 3a containing 274 amino acids with a theoretical mo-
lecular mass of approximately 30.9 kDa (Swiss-Prot: P59632).
Using BLAST program analysis [16], we showed that the N-
terminal domain of SARS protein 3a has 29% identity with
the putative cytochrome B-561 transmembrane protein from
bacteria (Ralstonia solanacearum) and 24% identity with the
opsin fragments from the hawkmoth (Manduca sexta) and the
rhodopsin from the butterﬂy (Popilio glaucus), as indicated in
Fig. 1. The C-terminus of protein 3a has moderate similarity to
the calcium-transporting ATPase (calcium pump) from a
parasite (Plasmodium falciparum) and the outer-membrane
porin from a bacterium (Shewanella oneidensis), 41% and 27%
identity, respectively. However, overall the putative full-length
sequence of protein 3a lacks signiﬁcant similarities to any
known proteins. When we used hydrophobicity and polarity
analysis programs [17,18], there were three regions with low
polarity and high hydrophobicity in the N-terminus of the
protein 3a sequence. Membrane-spanning regions, predicted
by the Dense Alignment Surface method [19], were located in
three sequence segments, amino acids 43–56, 79–97, andFig. 1. Sequence analysis of putative SARS-CoV protein 3a. Schematic rep
transmembrane protein from bacteria (R. solanacearum) (TrEMBL: Q8XVV8
butterﬂy (P. glaucus) (TrEMBL: Q9UAM8), calcium pump from parasite (P
bacteria (S. oneidensis) (TrEMBL: Q8EAK6). The numbering system is base106–116, suggesting that protein 3a may play a role in SARS-
CoV interaction with the cellular membrane. Based on bioin-
formation of this novel protein, we further demonstrate that
protein 3a is expressed both in SARS-CoV-infected cells and a
SARS-CoV-infected patient’s tissue, which is a ﬁrst step in
exploring its role in the SARS-CoV infection process.
3.2. Preparation of anti-serum to recombinant protein 3a
The cDNA of SARS protein 3a was obtained from the
SARS-CoV-TW1 strain by reverse-transcription PCR and was
subcloned to a pGEX 4T-2 vector. The protein 3a/GST-fusion
protein was expressed in E. coli and puriﬁed with glutathione
chromatography. To explore the possibility of immunologic
detection of SARS protein 3a, we prepared rabbit antibodies
to a synthetic peptide (P2), corresponding to amino acids 261–
274 of the putative SARS protein 3a. Western blot analysis
showed that partially puriﬁed recombinant protein 3a from
E. coli can be recognized by anti-P2 antibody (Fig. 2A, lane 3)
and pooled sera from SARS-CoV-infected patients (Fig. 2A,
lane 4). This protein was not detected by preimmune serum
(data not shown).
3.3. Expression of recombinant SARS protein 3a in Vero E6
cells
To determine whether recombinant protein 3a can be ex-
pressed in mammalian cells, the cDNA of protein 3a was
subcloned into the pcDNA3.1/myc-His vector and then
transfected into Vero E6 cells. However, expression of protein
3a was not detected in the Vero E6 cells by Western blot
analysis (data not shown). We also attempted to express SARS
protein 3a in several cell lines, but all attempts were unsuc-
cessful, suggesting that protein 3a was selectively expressed in
SARS-CoV-infected cells. We next used an infected–transfec-
tion transient expression system to enhance the expressed level
of protein 3a in Vero E6 cells [11–13]. Vero E6 cells were in-
fected with a vaccinia virus expressing T7 RNA polymerase for
2 h, then transfected with the pcDNA3.1/Myc-His/protein 3a
construct. Forty eight hours after infection-transfection, cellresentation of protein 3a aligned with the putative cytochrome B-561
), opsin from hawkmoth (M. sexta) (TrEMBL: O02465), rodopsin from
. falciparum) (Swiss Prot: Q08853), and outer-membrane porin from
d on the individual sequences.
Fig. 2. Expression and immunodetection of recombinant SARS-CoV
protein 3a in E. coli or Vero E6 cells. (A) Recombinant SARS protein
3a expressed and partially puriﬁed from E. coli cells was separated by
12.5% SDS–PAGE and transferred to PVDF membrane. Puriﬁed
protein was stained with Coomassie brilliant blue (lane 2) or probed
with anti-P2 antibody (lane 3) or pooled sera from SARS-CoV-
infected patients (lane 4). Molecular weight markers were in lane 1.
Recombinant protein 3a (33–34 kDa) containing additional 14
amino acids from pGEX 4T-2 vector was indicated. GST protein de-
graded from GST-protein 3a was also indicated. (B) A pcDNA3.1/
myc-His/protein 3a plasmid was transfected into vaccinia virus-
infected Vero E6 cells. After 48 h, non-infected–transfected cell lysates
(lanes 1 and 4), vaccinia virus-infected Vero E6 cell lysates (lanes 2 and
5), and infected–transfected cell lysates (lanes 3 and 6) were prepared
for Coomassie blue staining (lanes 1–3) and Western blot analysis with
anti-P2 antibody (lanes 4–6). This recombinant myc-His tagged pro-
tein 3a (37 kDa) contains additional 38 amino acids from pcDNA3.1/
myc-His vector.
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Fig. 2B shows that a myc-His tagged protein 3a with a mo-
lecular mass of 37 kDa in the infected–transfected cell lysatesFig. 3. Detection of protein 3a in SARS-CoV-infected cells. (A) Vero E6 cells
h (lanes 2–5) were harvested, treated with SDS-sample buﬀer, and separated
with Coomassie blue. (B) Protein samples in panel A were analyzed by West
pre-incubated with 5 lM of P2 peptide (lane 6). (C) Protein samples in panel
N1) antibody. Lower panels in B and C show longer exposure time for lanewas recognized by the anti-P2 antibody. No signal was de-
tected in the non-infected–transfected or vaccinia virus-
infected cell lysates. Our data demonstrated that the putative
SARS protein 3a can be expressed in E. coli and Vero E6 cells,
although the expression level is relatively low. We also showed
that SARS-CoV-infected patients’ sera appeared to have spe-
ciﬁc antibodies against the recombinant protein 3a. Moreover,
the P2 peptide from the C-terminus of protein 3a appeared to
be a good epitope for generating antibodies against protein 3a
that will be useful for further studies of SARS-CoV.
3.4. Detection of protein 3a in SARS-CoV-infected cells
To determine whether protein 3a can be detected in SARS-
CoV-infected cells, we infected Vero E6 cells with SARS-CoV
TW1 and harvested cells at the indicated time after infection.
Cell lysates were analyzed by Western blotting with anti-P2 or
anti-nucleocapsid (anti-N1) antibodies. Fig. 3 shows that ex-
pression of SARS protein 3a (panel B), like that of the viral
nucleocapsid protein (panel C), was detected at 8–12 h after
infection and reached a higher level after 24 h in the SARS-
CoV-infected Vero E6 cells. Anti-P2 antibody pre-incubated
with the P2 peptide, but not the N1 peptide, prevented binding
of anti-P2 antibodies to the protein 3a, indicating that protein
3a was speciﬁcally detected (Fig. 3B, lane 6; and data not
shown).
3.5. Detection of protein 3a in the lung tissue of a
SARS-CoV-infected patient
We next determined whether protein 3a could be detected in
a SARS-CoV-infected patient by immunohistochemistry (de-
scribed in Section 2). Our data showed that protein 3a was
detected only in the lung section (Fig. 4), but not in small in-
testine, heart, liver, spleen, kidney, and lymph node of the
SARS patient (data not shown). No staining was seen in the
lung tissue sections using rabbit pre-immune serum (data not
shown). The positive staining cells were mostly located in the
alveolar lining pneumocytes and some intra-alveolar cells. The
hyaline membrane along the alveolar space was occasionally
positive. The positive staining area tended to be found in the
periphery of the lung with a patch-like distribution. The
bronchial epithelium and the endothelium of pulmonary ves-uninfected (lane 1) or infected with SARS-CoV TW1 for 4, 8, 12, or 24
by 12.5% SDS–PAGE, transferred to PVDF membrane, and stained
ern blotting using an anti-P2 antibody (lanes 1–5) or anti-P2 antibody
A were analyzed by Western blotting using an anti-nucleocapsid (anti-
s 1–5.
Fig. 5. Subcellular localizationofprotein 3a inSARS-CoV-infected cells.
(A) Vaccinia virus-infected Vero E6 cells were transfected with the
pcDNA3.1/myc-His/protein 3a plasmid and grown on glass coverslips.
After 48 h, cells were ﬁxed with formaldehyde and incubated with anti-
P2 or anti-b-COP antibody (Golgi marker). (B) Commercial slides with
SARS-CoV-infected cells were examined by indirect immunoﬂuores-
cence staining and confocal microscopy. The left panels show protein 3a
or membrane (M) protein ﬂuorescence in green, the middle panels show
marker ﬂuorescence including 58 K protein (Golgi marker), b-COP
(Golgimarker), calnexin (ERmarker), LAMP-2 (lysosomemarker), and
cytochrome c oxidase subunit 1 (COX 1) (mitochondria marker) in red,
and the right panels show overlays of ﬂuorescence images of protein 3a
orM protein and the subcellular marker proteins where yellow indicates
co-localization of green (protein 3a or M protein) and red (marker
proteins) signals. Hoechst 33258 nuclearDNA staining is shown in blue.
The confocal ﬂuorescence was visualized by Bio-Rad Radiance 2100
confocal microscope (60). (C) Subcellular distribution of protein 3a.
Membrane (M), and cytosolic (C) fractions of recombinant protein 3a
expressed inVeroE6were prepared as described in Section 2. Equivalent
amounts (from total homogenate, T) of each fraction were analyzed by
electrophoresis and immunoblottingusing speciﬁc antibodies against the
P2 peptide of protein 3a, a-tubulin (cytosolic marker), or calnexin (ER
membrane marker).
Fig. 4. Immunohistochemical detection of protein 3a in lung section
from an SARS-CoV-infected patient. The expression of protein 3a was
detected using anti-P2 antibody diluted 1:500 as described in Section 2.
Arrowheads indicate protein 3a in the cytoplasm of some pneumocytes
(100).
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the tissue sections from non-SARS patients. Our data clearly
showed that protein 3a was expressed in the SARS-CoV-in-
fected lung tissue. The function of this molecule within the
alveolar lining pneumocytes was unclear, but its presence
highlights the importance of further characterization of this
novel protein and identiﬁcation of its interacting cellular
proteins in future studies.
3.6. Subcellular localization of SARS protein 3a
We next determined the subcellular localization of the SARS
protein 3a in Vero E6 cells by confocal microscopy and frac-
tionation. Fig. 5A shows that recombinant protein 3a ex-
pressed in Vero E6 cells as well as protein 3a in the SARS-
CoV-infected cells was distributed over the cytoplasm in a ﬁne
punctate pattern with partly concentrated staining in the Golgi
apparatus. Similar immunoﬂuorescence staining of protein 3a
was also observed in Vero cells after 6 h of infection with
SARS-CoV, however the expression level was lower than that
of 24 h (data not shown). Furthermore, by using commercially
prepared slides with SARS-CoV-infected cells (Euroimmun
Inc., Germany), we showed that the expression of protein 3a
was also detected in a punctate pattern with partly concen-
trated staining in the Golgi apparatus (Fig. 5B, a–f), but not
co-localized with endoplasmic reticulum (ER), lysosome, or
mitochondria (Fig. 5B, g–o). The distribution pattern of pro-
tein 3a as well as the SARS-CoV M protein was co-localized
with the b-COP Golgi apparatus marker protein shown in
Fig. 5B, d–f and p–r, respectively. To assess the subcellular
distribution of recombinant protein 3a expressed in Vero E6
cells, homogenates were fractionated by diﬀerential centrifu-
gation. Membrane (M) and cytosol (C) fractions were sepa-
rated and protein 3a, calnexin (ER membrane marker), and
a-tubulin (cytoplasmic marker) in subcellular fractions were
identiﬁed by Western blot analysis. Protein 3a was detected in
the membrane fraction (Fig. 5C). Our data demonstrate that
SARS-CoV indeed expressed the putative membrane-associ-
ated protein 3a in vivo. It is known that the viral membrane
proteins, including the major proteins S (spike) and M
(membrane), are inserted into the ER–Golgi intermediate
compartment, whereas full-length replicated RNA (+ strands)
116 C.-J. Yu et al. / FEBS Letters 565 (2004) 111–116assembles with the N (nucleocapsid) protein. This RNA pro-
tein complex then associates with the M protein embedded in
the membranes of the ER and virus particles form as the nu-
cleocapsid complex buds into the ER. The virus then migrates
through the Golgi complex and eventually exits from the cell,
probably by exocytosis [9,20–22]. It is of interest to note that
protein 3a was partially co-localized with Golgi marker protein
p58 and that the punctate pattern may be the result of protein
3a being a membrane-associated molecule. Whether protein 3a
can, like the S and M proteins, play a role in SARS-CoV as-
sembly in the ER–Golgi exocytosis pathway needs to be in-
vestigated further.
In conclusion, we have identiﬁed and characterized a novel
SARS-CoV protein, protein 3a, that lacks signiﬁcant identity
with any known proteins. Recently, based on molecular epi-
demiology and genome evolution studies of SARS-CoV, Yeh
et al. [23] reported that two of the 11 protein-coding regions in
the SARS-CoV genome, spike and orf3 (protein 3a), showed a
sign of positive selection during virus evolution. Although the
function(s) of protein 3a is yet to be known, the spike protein is
thought to be of particular importance in the infectious pro-
cess, based on the studies of other CoVs [24–26]. The high-
frequency mutations or evolution adaptive property of protein
3a implied that its function may be, like spike protein, very
important in the virus life cycle and/or disease development.
Our ﬁndings provide an opportunity to explore protein 3a’s
function in the SARS-CoV infection process. The SARS-CoV
protein 3a may provide insight into the mechanisms of infec-
tion of the virus as well as serve as a target for therapeutic
developments for this disease, allowing for rapid and rational
development and testing of candidate vaccines and therapeu-
tics against this important human pathogen.
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